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comparative analysis of obesity-
related cardiometabolic and renal 
biomarkers in human plasma and 
serum
Meenu Rohini Rajan1,2,16, Matus Sotak  1,2,16, Fredrik Barrenäs1,2,3, Tong Shen4, 
Kamil Borkowski4, Nicholas J. Ashton2,5,6,7, Christina Biörserud9, Tomas L. Lindahl10, 
Sofia Ramström10,11, Michael Schöll2,5,8, Per Lindahl1, Oliver fiehn  4, John W. newman  4,12,13, 
Rosie perkins 1, Ville Wallenius9, Stephan Lange  1,14 & emma Börgeson 1,2,15,17*
The search for biomarkers associated with obesity-related diseases is ongoing, but it is not clear 
whether plasma and serum can be used interchangeably in this process. Here we used high-throughput 
screening to analyze 358 proteins and 76 lipids, selected because of their relevance to obesity-
associated diseases, in plasma and serum from age- and sex-matched lean and obese humans. Most 
of the proteins/lipids had similar concentrations in plasma and serum, but a subset showed significant 
differences. Notably, a key marker of cardiovascular disease PAI-1 showed a difference in concentration 
between the obese and lean groups only in plasma. Furthermore, some biomarkers showed poor 
correlations between plasma and serum, including PCSK9, an important regulator of cholesterol 
homeostasis. Collectively, our results show that the choice of biofluid may impact study outcome when 
screening for obesity-related biomarkers and we identify several markers where this will be the case.
Obesity-related illness is an increasingly important global health issue that places a tremendous economic burden 
on society1. The negative health effects of prolonged obesity are partly fuelled by chronic low-grade inflammation, 
which contributes to cardiometabolic and kidney pathophysiology2–4. However, the exact mechanisms that link 
obesity with cardiometabolic and kidney diseases are unclear and remain a subject of intensive research. The 
search for biomarkers that assist in the identification of novel disease-related pathways is critical to develop new 
therapies that are tailored to subpopulations particularly prone to obesity-related pathophysiology.
Disease-related biomarkers are often identified and quantified in blood-derived plasma or serum5,6. 
Preparation of plasma and serum requires the removal of cellular components by centrifugation. Generation 
of plasma is preceded by the addition of an anti-coagulant (e.g. EDTA, heparin or citrate) to the whole blood. 
By contrast, the blood used for serum is allowed to clot before centrifugation, resulting in lower concentrations 
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of clotting factors (such as fibrinogen and coagulation cascade proteins) in serum than in plasma. The World 
Health Organization generally recommends using plasma as this more accurately reflects the physiological and/
or pathophysiological state of the patient7. However, biomarkers are often reported to have better detectability 
in serum8 despite the fact that serum has a slightly lower total protein concentration than plasma9. Indeed, some 
intracellularly stored proteins and lipids are only detectable upon coagulation-induced release from leukocytes 
and platelets, and serum is preferred in assays detecting, for example, cardiac troponins10–12. Importantly, the 
choice of biofluid is not merely a question of detectability, but it may also affect the conclusions drawn from a 
study. For example, Alsaif et al. showed that of 16 proteins (identified in either plasma or serum) that were dif-
ferentially expressed between healthy controls and subjects with bipolar disorder, only two showed differential 
expression in both serum and plasma13.
The aim of our study was to determine whether the use of plasma or serum would yield different results when 
screening for obesity-related biomarkers. We analyzed proteins and lipids that have previously been suggested to 
play a role in obesity-related cardiometabolic diseases in plasma and serum from age- and sex-matched groups of 
lean and obese humans. Our results show that the use of plasma or serum may have an effect on study outcome 
when screening for obesity-related biomarkers and we identify key markers that highlight this issue.
Results and Discussion
Detectability of proteins in plasma versus serum. We used four Olink multiplex protein panels 
(inflammation, cardiometabolic, cardiovascular II, cardiovascular III) selected on the basis of their relevance to 
obesity-related diseases to measure protein concentrations in plasma and serum from 11 obese subjects and 11 
age- and sex-matched lean controls. The characteristics of the human cohort are presented in Table 1. Of the 368 
proteins analyzed (10 of which were measured in duplicate panels, see Supplementary Table S1 for the full list), 
one protein (BDNF) was excluded due to technical issues, nine proteins (IL-1 alpha, IL-2, TSLP, IL-22 RA1, IL-13, 
TNF, IL-20, IL-33, IFN-gamma) were excluded because they were undetectable in both plasma and serum, and 23 
additional proteins were excluded because values were missing in >30% of the samples in all of the four groups 
(lean plasma, lean serum, obese plasma, obese serum; Supplementary Table S1). Detectability issues with one of 
the excluded proteins, NT-proBNP, have previously been reported14. In total, 335 proteins were included in the 
comparative analyses (Supplementary Fig. S1).
For the majority of proteins, their concentrations were similar between plasma and serum (Supplementary 
Fig. S2a,b). After adjusting for multiple comparisons using the stringent Holm-Bonferroni test, we found signifi-
cantly different concentrations between plasma and serum for 23.5% and 33.4% of proteins in the lean and obese 
cohorts, respectively [adjusted (adj.) p < 0.05, Fig. 1]. Most of these proteins were present at higher concentra-
tions in serum, which may partly be explained by the clotting-induced volume displacement effect15,16 and by the 
fact that coagulation elicits release of platelet granules and intracellularly stored cytokines17–19. The intracellularly 
stored protein MCP-1, for example, exhibited significantly higher concentrations in serum compared with plasma 
(in both the inflammation and the cardiovascular III panels) in the lean and obese groups. Of note, we did not 
record female menstruation cycle and/or menopausal state, which may affect platelet activation, although con-
flicting results have been shown20–25.
A subset of proteins with significantly different concentrations in plasma and serum (including HSP-27, PAR-
1, 4E-BP1 and SRC) exhibited lower concentrations in serum (Fig. 1). HSP-27 has been proposed as a biomarker 
for both cardiometabolic disease and cancer26, although controversial results have been reported27. Of note, a 
recent study showed that the concentration of HSP-27 increased by about three-fold with just one freeze-thaw 
cycle in plasma but was more stable in serum28. All of our samples underwent two freeze-thaw cycles, which 
could explain the higher detectability of HSP-27 in plasma. During coagulation, PAR-1 is cleaved29 and SRC30 and 
4-EBP131,32 become prone to degradation through proteolytic pathways, which likely explains their lower con-
centrations in serum. Furthermore, two proteins, AXIN1 and STK4, passed our cut-off criteria for detection in 
plasma but not in serum (Supplementary Table S1). Enrichment analysis of all the proteins that were significantly 
altered between plasma and serum confirmed the enrichment of pathways involved in neutrophil chemotaxis and 
platelet activation (Supplementary Fig. S2c, Supplementary Table S3).
Sensitivity of plasma versus serum when screening for obesity-related protein biomarkers. 
Most of the biomarkers that showed significantly different concentrations between the obese and lean groups were 
present at higher levels in the obese group; however, a small number (including IGFBP-1 and GH) showed lower 
concentrations in the obese group, with significant differences observed in both plasma and serum (Table 2). The 
Lean Obese
Men Women All Men Women All
Sex 3 8 3♂/8♀ 3 8 3♂/8♀
BMI (kg/m2) 23.3 ± 0.9 22.0 ± 1.0 22.4 ± 2.4 41.0 ± 2.1 44.4 ± 1.5 43.5 ± 4.1
Age (years) 42.3 ± 4.3 40.0 ± 5.3 40.6 ± 13.0 45.0 ± 3.1 40.4 ± 5.6 41.6 ± 13.6
Hormone replacement therapy — 0/8 — — 0/8 —
Hormonal contraceptive pill — 2/8 — — 0/8 —
Intrauterine contraceptive device — 0/8 — — 2/8 —
Table 1. Summary of cohort demographics. Data are shown as mean ± SEM.
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number of proteins with significantly different concentrations between the lean and obese groups was greater 
in serum (Table 2), in agreement with (1) an earlier study that reported higher sensitivity of serum to detect 
diabetes-associated differences in metabolite concentration33 and (2) the fact that obesity is associated with higher 
Figure 1. Detectability of proteins in plasma versus serum. Heatmaps showing protein biomarkers that 
exhibited significantly different concentrations in plasma versus serum in (a) lean subjects (n = 11) and (b) 
obese subjects (n = 11) after adjustment for multiple comparisons using the method of Holm-Bonferroni at adj. 
p < 0.05. Proteins that are significantly different in only one of the groups (lean or obese) are marked in bold. 
For proteins that are present in duplicate protein panels, the panel is indicated in parentheses: I, inflammation; 
CVII, cardiovascular II; and CVIII, cardiovascular III. Relative protein concentrations are reported as z-scores.
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leukocyte and platelet counts and increased platelet activation34,35. MCP-3 was present at higher concentrations 
in the obese versus lean group in serum but not plasma (Table 2), and showed low detectability in plasma in both 
groups (Supplementary Table S1). However, concentrations of PAI-1 were only significantly higher in the obese 
versus lean group in plasma despite showing higher detectability in serum (Table 2). This difference in sensitiv-
ity versus detectability for PAI-1 was confirmed by ELISA (Supplementary Fig. S3). PAI-1 inhibits fibrinolysis 
and has been proposed to be an important biomarker in cardiometabolic and diabetes research, although, as 
recently reviewed, conflicting results have been reported36. A possible explanation for this discrepancy, at least 
in part, may be due to the interchangeable use of plasma versus serum; indeed, studies comparing lean versus 
obese and/or diabetic groups have reported differences in PAI-1 levels when using plasma37 but not serum38. 
Coagulation-induced secretion of intracellular PAI-1 is likely responsible for the high serum levels of PAI-1, 
which may mask the differences between the lean and obese groups.
Protein correlations in plasma versus serum. For the correlation analysis, 316 proteins survived the 
cut-off criteria (Supplementary Fig. S1). We observed significant correlations between plasma and serum sam-
ples for most (68.8%) of the proteins analyzed in the lean and obese groups combined (Table 3), although fewer 
significant correlations were seen when dividing the cohort into obese and lean (Supplementary Table S4). Of 
the 10 proteins that were measured in duplicate panels, eight displayed similar correlations between plasma and 
serum. However, MCP-1 and uPA only showed a significant correlation between plasma and serum in one of the 
duplicate panels.
We observed good correlations between plasma and serum samples for leptin (r = 1.00, adj. p < 0.001) and 
IGFBP-1 (r = 0.98, adj. p < 0.001), which are proteins that exhibited obesity-associated differences in concen-
tration (Fig. 2a,b). Some proteins showed poor correlations, such as PCSK9 (r = 0.27, ns) and FGF-23 (r = 0.43 
and 0.64 in the inflammation and cardiovascular II panels, respectively, both ns) (Fig. 2c,d). PCSK9 binds to the 
receptor for low-density lipoprotein and PCSK9 inhibitors are therefore of intense interest to pharmaceutical 
companies39,40. Studies interchangeably measure PCSK9 in plasma41,42 and serum43,44, but our result indicates 
that the choice of biofluid could potentially have a significant impact on the conclusions drawn. Our panels also 
included the FDA-approved biomarkers KIM-1 and osteopontin, which are used to monitor kidney disease45,46. 
KIM-1 was well correlated between plasma and serum (r = 0.99, adj. p < 0.001) but osteopontin displayed a poor 
correlation (r = 0.46, ns) (Fig. 2e,f).
Lipids in plasma versus serum, and in lean versus obese groups. We also performed targeted lipi-
domics of inflammation-related lipids in plasma and serum from the lean and obese groups. Of the 76 lipids 
analyzed (see Supplementary Table S2), two were excluded as they did not survive the cut-off criteria for the com-
parative analysis (Supplementary Fig. S4). For most of the lipids, there were no major differences in concentration 
between plasma and serum (Supplementary Fig. S5). We observed that concentrations of 21.6% of the lipids in the 
lean cohort and 18.9% of the lipids in the obese cohort were significantly higher in serum than in plasma (after 
FDR adjustment, adj. p < 0.05); none of the lipids showed lower concentrations in serum (Fig. 3a,b). In total, 73 
lipids survived the cut-off for the correlation analyses; we observed significant correlations between plasma and 
serum for 64% of the analyzed lipids when analyzed in the lean and obese groups combined (Table 4), and fewer 
significant correlations were seen when dividing the cohort into obese and lean (Supplementary Table S5).
Four lipids showed significantly different concentrations between the obese and lean groups in plasma and/
or serum (Fig. 3c). Concentrations of AEA and 19,20-DiHDoPA were significantly different (higher for AEA and 
lower for 19,20-DiHDoPA in the obese group) in both plasma and serum, but concentrations of 15-HETE and 
11-HETE were significantly different (both higher in the obese group) only in plasma (Fig. 3c).
Concluding remarks. In this study, we investigated whether the use of plasma or serum would yield different 
results when screening for obesity-related biomarkers. For most of the proteins and lipids, their concentrations 
showed good correlations between plasma and serum. However, it is important to note that PCSK9 concentra-
tions did not correlate between plasma and serum, indicating that caution must be taken when comparing studies 
that use different biofluids. Although most of the protein and lipids had similar concentrations in plasma and 
serum, those that did differ were generally present at higher concentrations in serum. Importantly, we observed 
significantly higher concentrations of the key disease-associated biomarker PAI-1 in the obese group only in 
plasma and not in serum, despite the protein showing higher detectability in serum. This result highlights that 
sensitivity does not necessarily parallel detectability. Furthermore, some obesity-induced changes, for example of 
MCP-3 concentrations, were only detected in serum. Collectively, these findings show that care should be taken 
when choosing biofluids for the study of biomarkers, particularly those for which we report differences in sensi-
tivity/detectability between plasma and serum.
Methods
Study participants. We recruited obese subjects [body mass index (BMI) 35–55 kg/m2, aged 18–65 years] 
from a cohort scheduled to undergo gastric bypass surgery, as well as age- and sex-matched lean subjects (BMI 
18.5–24.9 kg/m2). Subjects were excluded if they were taking anti-inflammatory and/or immunosuppressive 
drugs, currently smoked, or had been diagnosed with significant gastrointestinal disease or inflammatory bowel 
disease. Study participants were enrolled in accordance with the Helsinki Declaration and provided written 
informed consent. The study was approved by the Gothenburg Ethical Review Board #682-14 (ClinicalTrials.gov 
NCT02322073).
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Protein
Plasma Serum
Lean Obese Obese vs 
lean log2 
ratio
H-B 
Adj. p 
value
FDR 
Adj. p 
value
Lean Obese Obese vs 
lean log2 
ratio
H-B 
Adj. p 
value
FDR 
Adj. p 
valueNPX (mean ± SEM) NPX (mean ± SEM)
4E-BP1 6.57 ± 0.21 7.54 ± 0.10 0.97 ns 0.0106 4.57 ± 0.10 6.18 ± 0.33 1.62 ns 0.0081
ADAM-TS13 5.17 ± 0.06 4.94 ± 0.04 −0.22 ns ns 6.38 ± 0.05 6.19 ± 0.03 −0.18 ns 0.0336
ADM 6.33 ± 0.06 7.11 ± 0.09 0.78 0.0002 0.0001 6.03 ± 0.08 6.82 ± 0.11 0.79 0.0032 0.0004
AGRP 3.64 ± 0.11 3.12 ± 0.07 −0.52 ns 0.0136 3.74 ± 0.13 3.10 ± 0.08 −0.64 ns 0.0081
AMBP 5.52 ± 0.02 5.72 ± 0.04 0.20 ns 0.0037 5.53 ± 0.05 5.78 ± 0.03 0.26 ns 0.0058
CCL3 (CVD II) 3.18 ± 0.04 3.67 ± 0.05 0.49 0.0002 0.0001 3.65 ± 0.07 4.13 ± 0.07 0.48 0.0241 0.0018
CCL4 6.04 ± 0.07 6.67 ± 0.13 0.63 ns 0.0095 7.33 ± 0.12 7.76 ± 0.19 0.43 ns ns
CCL18 5.28 ± 0.22 6.09 ± 0.19 0.81 ns ns 5.36 ± 0.21 6.25 ± 0.18 0.89 ns 0.0259
CCL19 8.98 ± 0.15 9.66 ± 0.13 0.68 ns 0.0246 9.16 ± 0.15 9.82 ± 0.12 0.66 ns 0.0222
CDCP1 1.56 ± 0.14 2.16 ± 0.17 0.60 ns ns 1.64 ± 0.14 2.37 ± 0.18 0.73 ns 0.0274
CES1 1.41 ± 0.05 2.04 ± 0.20 0.63 ns ns 1.31 ± 0.04 2.02 ± 0.16 0.71 ns 0.0136
CHI3L1 5.27 ± 0.21 6.21 ± 0.27 0.94 ns ns 5.60 ± 0.13 6.61 ± 0.27 1.01 ns 0.0266
CHL1 2.47 ± 0.09 2.14 ± 0.04 −0.33 ns 0.0406 2.64 ± 0.12 2.20 ± 0.05 −0.43 ns 0.0366
CSF-1 7.03 ± 0.06 7.30 ± 0.07 0.27 ns ns 7.13 ± 0.05 7.43 ± 0.08 0.30 ns 0.0349
CSTB 3.65 ± 0.14 4.27 ± 0.12 0.62 ns 0.0321 3.65 ± 0.13 4.54 ± 0.21 0.89 ns 0.0155
CTSD 3.76 ± 0.09 4.61 ± 0.11 0.85 0.0025 0.0003 4.14 ± 0.05 4.94 ± 0.14 0.79 0.0400 0.0026
CTSZ 3.81 ± 0.13 4.33 ± 0.12 0.52 ns ns 3.98 ± 0.06 4.46 ± 0.14 0.47 ns 0.0373
CXCL10 8.82 ± 0.17 9.51 ± 0.15 0.69 ns ns 8.70 ± 0.18 9.59 ± 0.15 0.89 ns 0.0127
CXCL11 6.36 ± 0.16 6.96 ± 0.18 0.60 ns ns 6.87 ± 0.16 7.94 ± 0.26 1.07 ns 0.0213
ENG 1.47 ± 0.07 1.40 ± 0.06 −0.07 ns ns 1.54 ± 0.05 1.31 ± 0.03 −0.23 ns 0.0183
FABP4 3.65 ± 0.30 5.57 ± 0.15 1.93 0.0115 0.0010 3.78 ± 0.26 5.72 ± 0.16 1.93 0.0024 0.0004
FCN2 4.48 ± 0.16 5.22 ± 0.10 0.74 ns 0.0106 4.04 ± 0.14 4.87 ± 0.10 0.83 0.0422 0.0026
FGF-21 (CVD II) 4.56 ± 0.43 7.12 ± 0.48 2.56 ns 0.0105 4.54 ± 0.43 7.03 ± 0.48 2.49 ns 0.0105
FGF-21 (I) 3.50 ± 0.41 5.98 ± 0.44 2.48 ns 0.0086 3.59 ± 0.40 6.03 ± 0.44 2.44 ns 0.0081
Gal-9 6.96 ± 0.04 7.51 ± 0.07 0.55 0.0019 0.0003 7.07 ± 0.06 7.64 ± 0.08 0.57 0.0045 0.0005
GH 9.51 ± 0.69 6.38 ± 0.66 −3.13 ns 0.0318 9.63 ± 0.69 6.46 ± 0.64 −3.17 ns 0.0222
GLO1 3.29 ± 0.10 3.78 ± 0.18 0.49 ns ns 4.66 ± 0.17 5.56 ± 0.25 0.90 ns 0.0415
HAOX1 2.90 ± 0.30 4.71 ± 0.41 1.80 ns 0.0220 2.97 ± 0.31 4.81 ± 0.42 1.84 ns 0.0183
HB-EGF 3.84 ± 0.09 3.94 ± 0.08 0.10 ns ns 5.32 ± 0.13 6.52 ± 0.16 1.20 0.0030 0.0004
HGF 6.76 ± 0.07 7.62 ± 0.14 0.86 0.0249 0.0019 7.58 ± 0.09 8.60 ± 0.14 1.02 0.0026 0.0004
IGFBP-1 3.85 ± 0.20 1.47 ± 0.26 −2.38 0.0002 0.0001 3.98 ± 0.18 1.55 ± 0.27 −2.44 0.0002 0.0002
IGFBP-2 6.65 ± 0.25 5.81 ± 0.12 −0.85 ns ns 6.84 ± 0.21 5.95 ± 0.11 −0.89 ns 0.0146
IL-1ra 5.33 ± 0.09 7.05 ± 0.21 1.72 0.0013 0.0003 5.80 ± 0.10 7.47 ± 0.20 1.67 0.0009 0.0004
IL-6 2.36 ± 0.17 4.17 ± 0.34 1.81 ns 0.0044 2.46 ± 0.16 4.22 ± 0.33 1.75 ns 0.0043
IL-10RB 6.34 ± 0.09 6.70 ± 0.08 0.36 ns 0.0473 6.53 ± 0.08 6.94 ± 0.08 0.41 ns 0.0146
IL-18 7.75 ± 0.14 8.47 ± 0.20 0.72 ns ns 7.88 ± 0.15 8.67 ± 0.22 0.79 ns 0.0396
IL-18R1 6.61 ± 0.11 7.16 ± 0.13 0.55 ns 0.0360 6.80 ± 0.09 7.37 ± 0.13 0.57 ns 0.0188
KIT 3.31 ± 0.08 2.84 ± 0.09 −0.47 ns 0.0095 3.29 ± 0.08 2.99 ± 0.10 −0.30 ns ns
LAP TGF-β−1 5.64 ± 0.11 6.01 ± 0.08 0.38 ns ns 6.94 ± 0.09 7.28 ± 0.08 0.34 ns 0.0417
LEP 4.06 ± 0.32 6.66 ± 0.11 2.60 0.0019 0.0003 4.09 ± 0.34 6.81 ± 0.11 2.72 0.0018 0.0004
LILRB2 2.18 ± 0.09 2.62 ± 0.08 0.44 ns 0.0225 2.11 ± 0.11 2.68 ± 0.08 0.58 ns 0.0083
LTBR 1.75 ± 0.12 2.02 ± 0.08 0.27 ns ns 1.84 ± 0.03 2.10 ± 0.05 0.26 ns 0.0043
MCP-1 9.35 ± 0.07 9.87 ± 0.05 0.52 0.0058 0.0005 10.52 ± 0.13 11.02 ± 0.13 0.51 ns ns
MCP-3 1.39 ± 0.00 1.48 ± 0.04 0.09 ns ns 1.42 ± 0.02 2.07 ± 0.10 0.65 0.0254 0.0018
MCP-4 2.19 ± 0.16 2.72 ± 0.12 0.53 ns ns 3.56 ± 0.17 4.36 ± 0.22 0.80 ns 0.0450
MIP-1 alpha (I) 3.35 ± 0.03 3.83 ± 0.06 0.48 0.0027 0.0003 3.72 ± 0.07 4.28 ± 0.08 0.56 0.0107 0.0009
MPO 2.30 ± 0.23 2.91 ± 0.08 0.61 ns ns 2.92 ± 0.13 3.52 ± 0.12 0.59 ns 0.0222
NCAM1 2.27 ± 0.09 1.89 ± 0.06 −0.38 ns 0.0191 2.26 ± 0.10 1.90 ± 0.08 −0.36 ns ns
NEMO 3.40 ± 0.17 3.76 ± 0.22 0.36 ns ns 1.58 ± 0.04 2.27 ± 0.18 0.69 ns 0.0223
OSM 2.40 ± 0.12 3.39 ± 0.21 1.00 ns 0.0106 3.95 ± 0.16 5.14 ± 0.29 1.19 ns 0.0208
PAI-1 3.49 ± 0.31 5.80 ± 0.23 2.31 0.0030 0.0003 7.21 ± 0.09 7.60 ± 0.07 0.39 ns 0.0274
PLC 5.00 ± 0.14 5.45 ± 0.07 0.45 ns ns 5.23 ± 0.06 5.61 ± 0.03 0.38 0.0064 0.0006
PON3 5.45 ± 0.26 4.29 ± 0.27 −1.17 ns 0.0406 5.43 ± 0.21 4.22 ± 0.26 −1.22 ns 0.0146
PRCP 0.78 ± 0.07 1.11 ± 0.06 0.33 ns 0.0231 0.68 ± 0.05 1.11 ± 0.06 0.43 0.0067 0.0006
Continued
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Blood collection. Venous blood samples obtained from study participants after an overnight fast were 
collected in eitherplasma tubes spray coated with K2EDTA (Greiner Bio One) or serum tubes containing inert 
separator gel and silica particles as clot activator (Greiner Bio One). Plasma samples were centrifuged immedi-
ately whereas serum samples were allowed to clot for 30 min at room temperature before centrifugation (10 min 
at room temperature, 3,000 rpm Hettich EBA200). Samples were snap-frozen in liquid nitrogen and stored at 
−80 °C until analysis.
Multiplex protein assay. Protein biomarkers were analyzed using the proximity extension assay, using 
four protein panels (inflammation, cardiometabolic, cardiovascular II and cardiovascular III) (Olink Proteomics, 
Uppsala, Sweden) at the Clinical Biomarkers Facility at Science for Life Laboratory (Uppsala University, Sweden) 
according to the manufacturer’s instructions. Briefly, 1 µl plasma or serum was incubated with a mixture of 92 
proximity antibody pairs tagged with oligonucleotides in a 96-well plate. In this assay, once a pair of antibodies 
binds to their corresponding antigens in close proximity, linked oligonucleotides hybridize into double stranded 
DNA, which is further extended and amplified, and ultimately quantified by high-throughput real-time PCR 
(BioMark™ HD System, Fluidigm Corporation). To avoid intra-assay variability, plasma and serum samples were 
analyzed on the same plate.
ELISA. Plasma and serum PAI-1 levels were measured using a commercially available ELISA for Human Total 
Serpin E1/PAI-1 (#DY9387-05, R&D), according to the manufacturer’s instructions. To ensure that the protein 
was quantified within the linear range of the standard curve, plasma and serum were diluted 1:100 and 1:500, 
respectively.
Measurements of oxylipins, endocannabinoids and ceramides. Oxylipins, endocannabinoids, and 
ceramides in plasma and serum were isolated and quantified using modifications of published protocols47–49. 
Briefly, plasma or serum aliquots (40 µl) were spiked with deuterated oxylipin, endocannabinoid and ceramide 
surrogates, mixed with butylated hydroxyl toluene and ethylene diamine tetraacetic acid, and extracted with 
200 µl isopropanol containing the internal standards 1-cyclohexyl ureido, 3-dodecanoic acid and 1-phenyl ureido 
3-hexanoic acid in isopropanol. The homogenate was then centrifuged (10 min, 4 °C, 15,000 g) and the isopro-
panol supernatant was collected and stored at −20 °C until analysis.
Analytes were separated using a Waters Acquity ultra-performance liquid chromatography (UPLC; Waters, Milford, 
MA) on a 2.1 mm × 150 mm, 1.7 µm BEH C18 column (Waters) for analysis of oxylipins and endocannabinoids, and 
2.1 mm × 150 mm, 1.7 µm BEH C8 column (Waters) for analysis of ceramides. Separated analytes were detected by tan-
dem mass-spectrometry, using electrospray ionization with multi reaction monitoring on an API 6500 QTRAP (Sciex, 
Protein
Plasma Serum
Lean Obese Obese vs 
lean log2 
ratio
H-B 
Adj. p 
value
FDR 
Adj. p 
value
Lean Obese Obese vs 
lean log2 
ratio
H-B 
Adj. p 
value
FDR 
Adj. p 
valueNPX (mean ± SEM) NPX (mean ± SEM)
PRSS8 8.75 ± 0.08 9.20 ± 0.08 0.45 ns 0.0106 8.93 ± 0.09 9.43 ± 0.08 0.50 ns 0.0073
RARRES2 9.60 ± 0.13 10.22 ± 0.07 0.62 ns 0.0106 9.97 ± 0.09 10.44 ± 0.05 0.48 ns 0.0036
SCGB3A2 2.12 ± 0.26 0.96 ± 0.12 −1.15 ns 0.0130 2.23 ± 0.26 0.98 ± 0.13 −1.25 ns 0.0081
SELE 2.10 ± 0.13 2.81 ± 0.12 0.70 ns 0.0095 2.26 ± 0.12 2.93 ± 0.14 0.67 ns 0.0146
SPON2 9.78 ± 0.04 10.01 ± 0.04 0.24 ns 0.0036 10.31 ± 0.05 10.54 ± 0.03 0.23 ns 0.0105
STAMPB 3.16 ± 0.12 3.56 ± 0.15 0.41 ns ns 1.84 ± 0.04 2.38 ± 0.16 0.54 ns 0.0450
t-PA 4.06 ± 0.20 5.23 ± 0.09 1.17 0.0276 0.0019 4.28 ± 0.24 5.89 ± 0.09 1.61 0.0082 0.0007
TGM2 6.03 ± 0.13 6.35 ± 0.08 0.32 ns ns 3.85 ± 0.08 4.66 ± 0.17 0.81 ns 0.0082
TNF-R1 4.69 ± 0.14 5.27 ± 0.06 0.58 ns 0.0220 5.01 ± 0.06 5.53 ± 0.06 0.52 0.0019 0.0004
TNF-R2 3.24 ± 0.13 3.64 ± 0.04 0.41 ns ns 3.42 ± 0.07 3.77 ± 0.07 0.35 ns 0.0146
TNFRSF10A 2.06 ± 0.05 2.27 ± 0.07 0.22 ns ns 2.13 ± 0.07 2.42 ± 0.07 0.29 ns 0.0462
TNFRSF11A 4.04 ± 0.09 4.60 ± 0.08 0.56 ns 0.0036 4.40 ± 0.12 4.94 ± 0.08 0.54 ns 0.0146
TNFSF14 2.96 ± 0.08 3.73 ± 0.08 0.77 0.0004 0.0001 4.23 ± 0.12 4.97 ± 0.19 0.74 ns 0.0274
TR-AP 3.40 ± 0.14 3.89 ± 0.08 0.49 ns ns 3.54 ± 0.14 4.12 ± 0.10 0.58 ns 0.0266
TRAIL-R2 4.40 ± 0.09 4.66 ± 0.05 0.26 ns ns 4.59 ± 0.09 4.89 ± 0.05 0.30 ns 0.0481
TRAIL 7.25 ± 0.09 7.61 ± 0.08 0.36 ns ns 7.49 ± 0.09 7.92 ± 0.09 0.43 ns 0.0213
U-PAR 3.28 ± 0.15 3.64 ± 0.06 0.36 ns ns 3.78 ± 0.07 4.26 ± 0.10 0.48 ns 0.0104
VEGF-A 9.19 ± 0.06 9.58 ± 0.05 0.40 0.0196 0.0016 9.85 ± 0.13 10.40 ± 0.09 0.55 ns 0.0213
vWF 3.18 ± 0.18 3.55 ± 0.11 0.37 ns ns 6.21 ± 0.15 6.95 ± 0.18 0.73 ns 0.0349
Table 2. Proteins that exhibited significant differences in concentrations between obese and lean groups in 
plasma and/or serum. Differences in mean normalized protein expression (NPX) values between obese and 
lean groups are reported as a log2 ratio. p values were adjusted for multiple comparisons using either Holm-
Bonferroni (H-B) or false discovery rate (FDR); ns, not significant (adj. p > 0.05). For proteins that are present 
in duplicate protein panels, the panel is indicated in parentheses: I, inflammation; CVII, cardiovascular II; and 
CVIII, cardiovascular III.
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Inflammation Cardiometabolic Cardiovascular II Cardiovascular III
Protein r
H-B Adj. p 
value Protein r
H-B Adj. p 
value Protein r
H-B Adj. p 
value Protein r
H-B Adj. p 
value
FGF-21 1.00 1.57E-20 MBL2 0.99 2.79E-15 GH 1.00 1.47E-25 IGFBP-1 0.98 4.93E-13
FGF-19 0.99 1.11E-15 FCGR2A 0.98 6.92E-14 FGF-21 1.00 1.82E-22 Ep-CAM 0.97 1.47E-11
CCL20 0.99 7.03E-15 LILRB5 0.97 5.69E-12 LEP 1.00 2.85E-21 FABP4 0.96 1.32E-10
IL-18 0.98 3.69E-14 FCN2 0.97 9.41E-11 HAOX1 1.00 8.14E-20 CHIT1 0.96 1.85E-10
MMP-10 0.98 1.01E-13 LYVE1 0.96 6.02E-10 SERPINA12 0.99 1.00E-17 TFF3 0.96 2.79E-10
CXCL9 0.98 2.95E-13 CCL18 0.95 1.43E-09 IL-6 0.99 1.90E-16 SCGB3A2 0.95 3.62E-09
CDCP1 0.97 2.68E-11 COMP 0.95 6.47E-09 FABP2 0.99 8.91E-16 IGFBP-2 0.94 2.47E-08
TRANCE 0.97 6.59E-11 TIMD4 0.95 9.36E-09 KIM-1 0.99 2.38E-14 CCL24 0.94 2.85E-08
MCP-2 0.97 1.05E-10 THBS4 0.94 1.10E-08 IL-18 0.98 3.44E-13 PON3 0.94 3.53E-08
CCL19 0.96 4.09E-10 IGLC2 0.94 2.73E-08 GIF 0.98 1.35E-12 TR 0.93 9.55E-08
IL-12B 0.96 1.30E-09 REG1A 0.94 3.16E-08 CTRC 0.98 2.26E-12 CCL22 0.92 1.88E-07
OPG 0.95 4.06E-09 CR2 0.94 3.88E-08 MMP-12 0.98 4.02E-12 t-PA 0.92 2.80E-07
PD-L1 0.95 4.80E-09 FCGR3B 0.93 5.93E-08 REN 0.97 1.18E-11 CPA1 0.92 5.11E-07
CXCL10 0.95 9.69E-09 PRSS2 0.93 7.84E-08 IL-1ra 0.97 1.28E-11 DLK-1 0.91 8.47E-07
IL-18R1 0.94 1.68E-08 ANGPTL3 0.93 1.56E-07 SCF 0.97 4.73E-11 CPB1 0.91 9.00E-07
Flt3L 0.93 7.43E-08 SAA4 0.93 1.61E-07 ADM 0.96 1.70E-10 TNFRSF10C 0.90 1.99E-06
uPA 0.93 8.58E-08 TNC 0.92 2.47E-07 ACE2 0.96 1.05E-09 CHI3L1 0.89 4.47E-06
CD6 0.93 1.38E-07 NRP1 0.92 2.75E-07 LPL 0.95 2.47E-09 CCL15 0.89 6.88E-06
SCF 0.93 1.45E-07 DPP4 0.92 5.55E-07 MMP-7 0.95 2.92E-09 MMP-3 0.89 7.27E-06
CCL23 0.92 2.06E-07 CRTAC1 0.90 2.52E-06 PRSS8 0.95 3.92E-09 TIMP4 0.88 1.43E-05
TNFB 0.92 2.87E-07 APOM 0.89 5.45E-06 XCL1 0.95 7.68E-09 LDL receptor 0.87 2.59E-05
TRAIL 0.91 6.72E-07 GP1BA 0.89 6.21E-06 VEGF-D 0.95 8.75E-09 SELE 0.87 3.29E-05
CD244 0.91 6.72E-07 LILRB2 0.89 7.09E-06 TNFRSF13B 0.94 1.13E-08 ST2 0.84 0.0002
CCL25 0.90 2.94E-06 FETUB 0.89 8.64E-06 HO-1 0.94 1.23E-08 IL-6RA 0.84 0.0002
OSM 0.87 2.65E-05 CDH1 0.88 1.36E-05 BMP-6 0.93 6.58E-08 CTSZ 0.83 0.0003
CCL11 0.87 3.92E-05 TIE1 0.88 1.95E-05 IgG Fc R II-b 0.93 7.84E-08 SHPS-1 0.81 0.0008
CST5 0.86 5.29E-05 NCAM1 0.87 2.06E-05 IL16 0.93 8.80E-08 CTSD 0.81 0.0009
CCL28 0.85 0.0001 TCN2 0.87 2.34E-05 RAGE 0.93 1.07E-07 CCL16 0.80 0.001
IL-10RB 0.85 0.0001 AOC3 0.87 3.12E-05 TIE2 0.93 1.26E-07 GDF-15 0.80 0.001
HGF 0.85 0.0001 VCAM1 0.85 0.0001 MERTK 0.92 3.06E-07 Gal-4 0.79 0.002
CCL4 0.84 0.0001 TGFBI 0.84 0.0002 TF 0.92 4.20E-07 CD93 0.79 0.002
TNFRSF9 0.84 0.0002 F7 0.84 0.0002 TRAIL-R2 0.92 4.51E-07 CD163 0.78 0.003
CSF-1 0.83 0.0003 C2 0.84 0.0002 IL27 0.92 4.63E-07 RARRES2 0.77 0.004
IL-8 0.83 0.0004 ANG 0.84 0.0002 Gal-9 0.91 6.07E-07 IL2-RA 0.75 0.007
MIP-1α 0.82 0.0005 SERPINA7 0.83 0.0004 IL1RL2 0.91 9.77E-07 RETN 0.75 0.008
CXCL11 0.79 0.002 OSMR 0.83 0.0004 AGRP 0.91 1.06E-06 BLM hydrol. 0.75 0.008
ADA 0.78 0.003 IGFBP6 0.82 0.0005 CTSL1 0.91 1.53E-06 MPO 0.74 0.009
TWEAK 0.78 0.003 ICAM3 0.81 0.0008 TNFRSF11A 0.90 2.86E-06 IL-17RA 0.73 0.01
MCP-4 0.78 0.003 PROC 0.81 0.0008 CD4 0.89 7.67E-06 TNF-R1 0.73 0.01
CD5 0.77 0.004 ICAM1 0.80 0.001 TM 0.88 1.09E-05 ICAM-2 0.73 0.01
CD40 0.77 0.004 QPCT 0.79 0.002 MARCO 0.88 1.12E-05 TLT-2 0.73 0.02
4E-BP1 0.76 0.006 PRCP 0.79 0.002 FS 0.88 1.15E-05 IL-18BP 0.72 0.02
LIF-R 0.76 0.007 IL7R 0.79 0.002 DCN 0.87 3.66E-05 IL-1RT2 0.72 0.02
DNER 0.75 0.007 C1QTNF1 0.78 0.003 SOD2 0.86 5.53E-05 PI3 0.71 0.02
IL-10 0.75 0.008 CHL1 0.78 0.003 CCL3 0.85 9.10E-05 PAI-1 0.71 0.02
MMP-1 0.73 0.01 SERPINA5 0.77 0.004 hOSCAR 0.84 0.0002 COL1A1 0.71 0.02
MCP-1 0.70 0.03 SPARCL1 0.77 0.004 PD-L2 0.83 0.0004 MEPE 0.71 0.02
TNFSF14 0.70 0.03 IGFBP3 0.76 0.005 THBS2 0.82 0.0005 TFPI 0.71 0.02
EN-RAGE 0.69 0.04 NID1 0.76 0.006 PlGF 0.82 0.0005 OPG 0.70 0.03
β-NGF 0.69 0.04 SELL 0.76 0.007 Protein BOC 0.82 0.0005 MB 0.69 0.04
VEGF-A 0.68 0.048 PCOLCE 0.75 0.008 PAR-1 0.81 0.0009 TR-AP 0.69 0.04
SLAMF1 0.65 ns CST3 0.75 0.008 PRELP 0.77 0.004 PLC 0.64 ns
CXCL6 0.62 ns CD59 0.74 0.01 AMBP 0.76 0.005 vWF 0.64 ns
LAP TGF-β-1 0.59 ns GAS6 0.74 0.01 SORT1 0.76 0.006 MMP-9 0.63 ns
CXCL1 0.56 ns CFHR5 0.73 0.01 VSIG2 0.76 0.006 CDH5 0.63 ns
Continued
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Redwood City, CA) for oxylipins and endocannabinoids, and an API 4000 QTRAP (Sciex) for ceramides. Analytes 
were quantified using internal standard methods and 7–9 point calibration curves of authentic standards.
Measurement of non-esterified fatty acids. Non-esterified fatty acids in plasma and serum were 
isolated and converted to fatty acid methyl esters (FAMEs) as previously reported47. Briefly, plasma or serum 
aliquots (50 µl) were spiked with lipid class surrogates, mixed with 410 µl isopropanol, followed by 520 µl 
cyclohexane and 570 µl 0.1 M ammonium acetate. Samples were then centrifuged (5 min, 4 °C, 15,000 g), the 
upper organic phase was collected, and the remainder was re-extracted with a second 520 µl cyclohexane ali-
quot. The samples were then dried by vacuum centrifugation and reconstituted in 100 µl toluene and 180 µl 
methanol. To prepare FAMEs, 280 µl of toluene/methanol extracts were enriched with 20 µl methanol contain-
ing 60 µM C15:1n5 and incubated with 45 µl 2 M TMS-diazomethane in hexane (Sigma-Aldrich, St. Louis MO) 
for 30 min at room temperature. Samples were dried under vacuum and the residue was dissolved in 100 µl 
hexane containing 4 µM C23:0, which acted as an internal standard. Samples were then stored at −20 °C until 
analysis.
Inflammation Cardiometabolic Cardiovascular II Cardiovascular III
Protein r
H-B Adj. p 
value Protein r
H-B Adj. p 
value Protein r
H-B Adj. p 
value Protein r
H-B Adj. p 
value
CXCL5 0.56 ns ST6GAL1 0.72 0.02 SPON2 0.73 0.01 PSP-D 0.63 ns
CX3CL1 0.55 ns LILRB1 0.71 0.03 CCL17 0.73 0.01 uPA 0.62 ns
STAMPB 0.47 ns F11 0.64 ns CD84 0.70 0.03 GRN 0.62 ns
FGF-23 0.43 ns CA4 0.62 ns THPO 0.64 ns ITGB2 0.62 ns
FGF-5 0.42 ns TIMP1 0.62 ns IDUA 0.64 ns Gal-3 0.61 ns
CASP-8 0.25 ns LCN2 0.62 ns FGF-23 0.63 ns AXL 0.60 ns
ST1A1 0.23 ns PAM 0.56 ns GLO1 0.63 ns PGLYRP1 0.60 ns
IL-7 0.18 ns VASN 0.54 ns PSGL-1 0.61 ns CSTB 0.59 ns
TGF-α 0.18 ns KIT 0.52 ns CXCL1 0.60 ns PECAM-1 0.59 ns
ARTN # # CNDP1 0.51 ns PRSS27 0.53 ns TNF-R2 0.58 ns
AXIN1 # # TNXB 0.51 ns ANG-1 0.52 ns U-PAR 0.58 ns
GDNF # # ENG 0.50 ns LOX-1 0.52 ns TNFRSF14 0.58 ns
IL-10RA # # MET 0.49 ns ADAM-TS13 0.48 ns CNTN1 0.56 ns
IL-15RA # # GNLY 0.48 ns TGM2 0.48 ns Notch 3 0.53 ns
IL-17A # # TGFBR3 0.48 ns PTX3 0.48 ns FAS 0.53 ns
IL-17C # # CD46 0.47 ns CEACAM8 0.44 ns IGFBP-7 0.52 ns
IL-20RA # # CA1 0.45 ns GDF-2 0.42 ns TNFSF13B 0.51 ns
IL-22RA1 # # PLXNB2 0.44 ns CD40-L 0.39 ns IL-1RT1 0.51 ns
IL-24 # # EFEMP1 0.43 ns Dkk-1 0.36 ns AP-N 0.51 ns
IL-2RB # # CCL14 0.39 ns HB-EGF 0.31 ns SELP 0.50 ns
IL-4 # # CA3 0.38 ns PDGF-B 0.31 ns CXCL16 0.49 ns
IL-5 # # COL18A1 0.36 ns SRC 0.26 ns MMP-2 0.49 ns
IL-6 # # NOTCH1 0.35 ns PIgR 0.24 ns OPN 0.46 ns
LIF # # PTPRS 0.32 ns IL-17D 0.24 ns PRTN3 0.44 ns
MCP-3 # # CCL5 0.22 ns HSP 27 0.20 ns LTBR 0.38 ns
NRTN # # MFAP5 0.21 ns BNP # # SPON1 0.36 ns
NT3 # # MEGF9 0.11 ns CA5A # # MCP-1 0.34 ns
SIRT2 # # CES1 # # DECR1 # # ALCAM 0.28 ns
IFN-γ nd nd DEFA1 # # GT # # PCSK9 0.27 ns
IL-1α nd nd FAP # # IL-4RA # # JAM-A 0.24 ns
IL-13 nd nd ITGAM # # ITGB1BP2 # # CASP-3 0.20 ns
IL-2 nd nd LTBP2 # # NEMO # # PDGF-A 0.16 ns
IL-20 nd nd PLA2G7 # # PAPPA # # KLK6 0.15 ns
IL-33 nd nd PLTP # # PARP-1 # # AZU1 0.10 ns
TNF nd nd REG3A # # SLAMF7 # # EGFR −0.02 ns
TSLP nd nd SOD1 # # STK4 # # EPHB4 # #
BDNF Ϯ Ϯ UMOD # # TNFRSF10A # # NT-Pro-BNP # #
Table 3. Correlations of protein concentrations in plasma versus serum in all subjects. Pearson correlations 
(r) between NPX values in plasma and serum samples from the total cohort (n = 22) are shown. p values were 
adjusted by the Holm-Bonferroni (H-B) multiple comparison test; ns, not significant (adj. p > 0.05). nd, not 
detected. #Excluded due to too many missing values. Ϯ, removed due to technical issue.
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FAMEs were separated on a 30 m × 0.25 mm × 0.25 µm DB-225 ms column in a 6890 gas chromatogram inter-
faced with a 5973A mass selective detector (Agilent Technologies, Santa Clara, CA). All fatty acids were quanti-
fied against a 7-point calibration curves of authentic standards. Peak identifications were based on retention times 
and m/z ratios, with peak confirmation by inspection of simultaneously acquired full scan spectra collected from 
50–400 m/z. Calibrants and internal standards were purchased from NuchekPrep (Elysian, MN), Sigma-Aldrich, 
or Avanti Polar Lipids. Data were quantified using Chemstation vE.02.14 (Agilent Technologies) against 6–8 point 
calibration curves.
Figure 2. Protein correlations in plasma versus serum. Pearson correlations (r) between normalized protein 
expression (NPX) values for proteins in plasma and serum samples. Each data point is from one individual 
(open triangles: obese; closed triangles: lean). p values were adjusted by the Holm-Bonferroni multiple 
comparison test.
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Statistical analysis. Data are reported for proteins and lipids that had <30% missing values in: (1) at least 
one of the four groups (lean plasma, lean serum, obese plasma, obese serum) for the comparative analyses or (2) 
all of the four groups for the plasma-serum correlations.
Statistical analysis of the protein multiplex data was done in the R environment (version 3.5.1) using packages 
gplots (3.0.1) and gdata (2.18.0)50. For the proteins reported, missing values were replaced with limit of detection 
(LOD) values. Hierarchical clustering with Pearson correlation distance and complete linkage confirmed that 
the dataset did not include outliers. Concentrations of proteins are reported as normalized protein expression 
(NPX) values, an arbitrary unit on a log2 scale. Heatmaps were generated using hierarchical clustering based on 
correlation distance and Ward’s (ward.D2) clustering. Comparisons of protein levels using Student’s t-test were 
paired when comparing individual donor plasma versus serum values and unpaired when comparing the lean 
versus obese groups; p values were adjusted for multiple comparisons using either the stringent Holm-Bonferroni 
test or the commonly used false discovery rate (FDR) test as indicated (adjusted p values < 0.05 were consid-
ered significant). Pearson coefficient of correlation (r) values were calculated and p values were adjusted by the 
Holm-Bonferroni multiple comparison test.
The pathway enrichment analysis for proteins was done using Metascape51. Briefly, Gene IDs corresponding 
to significantly altered proteins were analysed, using the 325 unique proteins that survived the cut-off criteria as 
Figure 3. Oxylipins in plasma versus serum, and in lean versus obese groups. Heatmaps showing lipids that 
exhibited significantly different concentrations in plasma versus serum in (a) lean subjects (n = 11) and (b) 
obese subjects (n = 11) after adjustment for multiple comparisons using the false discovery rate (FDR) test 
at adj. p < 0.05. Lipids that are significantly different in only one of the groups (lean or obese) are marked 
in bold. Relative lipid concentrations are reported as z-scores. (c) Lipids that showed significantly different 
concentrations between the obese and lean groups in plasma and/or serum after FDR adjustment.
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Lipid r H-B Adj. p value
9,10-DiHOME 0.99 1.78E-18
9,10-DiHODE 0.99 9.18E-18
13-HODE 0.99 2.59E-15
12,13-DiHOME 0.99 3.83E-15
15,16-DiHODE 0.98 4.77E-13
19,20-DiHDoPA 0.97 1.26E-12
9-HOTE 0.97 3.93E-12
9-HODE 0.97 1.18E-11
13-HOTE 0.96 1.48E-10
12(13)-EpOME 0.96 2.04E-10
15(16)-EpODE 0.94 7.71E-09
DHA 0.93 1.60E-08
C16:1n7 0.93 3.84E-08
EPA 0.90 5.81E-07
C18:2n6 0.90 6.28E-07
C14:0 0.89 1.40E-06
AA 0.89 1.83E-06
C18:1n9 0.89 2.17E-06
C12:0 0.88 2.80E-06
DHEA 0.88 2.94E-06
C18:1n7 0.87 5.36E-06
ALA 0.87 7.22E-06
C14 Ceramide 0.87 8.78E-06
C18:3n3 0.85 2.07E-05
C20:5n3 0.84 4.24E-05
PGF2a 0.84 4.75E-05
LEA 0.84 5.45E-05
NA-Gly 0.83 9.19E-05
aLEA 0.83 9.19E-05
LA 0.82 0.0001
C16 Ceramide 0.82 0.0001
C24 dihydroceramide 0.81 0.0002
AEA 0.79 0.0005
1/2-LG 0.78 0.0008
17,18-DiHETE 0.75 0.002
C18:1 Ceramide 0.75 0.002
C24 Ceramide 0.75 0.002
C15:0 0.75 0.002
9(10)-EpOME 0.72 0.005
C18 Ceramide 0.71 0.007
1/2-AG 0.70 0.01
C17:0 0.68 0.01
11,12-DiHETrE 0.67 0.02
C16:0 0.67 0.02
4-HDoHE 0.66 0.02
C20 Ceramide 0.64 0.04
1/2-OG 0.64 0.04
C16:1n7t 0.59 ns
14,15-DiHETrE 0.59 ns
Dihomo GLA EA 0.56 ns
C20:1n9 0.55 ns
C20:2n6 0.54 ns
5-HETE 0.53 ns
12(13)-Ep-9-KODE 0.51 ns
5-HEPE 0.50 ns
DEA 0.49 ns
Continued
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the background list. A Gene Ontology category was deemed significantly enriched if the p value was lower than 
0.01 and displayed a minimum enrichment of 1.5.
Statistical analysis of the lipidomics data was done in MetaboAnalyst52. For the lipids reported, missing values 
were replaced with half of the lowest reported value. Fatty acid data normalization was optimized in Jmp Pro v 
12.0 and confirmed using the Shapiro-Wilk normality test. For statistical analysis, data points underwent log 
transformation and pareto scaling. Heatmaps were generated using hierarchical clustering based on Euclidean’s 
method of distance calculation and Ward’s clustering. Unadjusted p values were adjusted using FDR (adjusted p 
values < 0.05 were considered significant).
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